JPH0455440B2 - - Google Patents
Info
- Publication number
- JPH0455440B2 JPH0455440B2 JP60135808A JP13580885A JPH0455440B2 JP H0455440 B2 JPH0455440 B2 JP H0455440B2 JP 60135808 A JP60135808 A JP 60135808A JP 13580885 A JP13580885 A JP 13580885A JP H0455440 B2 JPH0455440 B2 JP H0455440B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- igg
- immunoglobulin
- binding
- column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 19
- 229940027941 immunoglobulin g Drugs 0.000 claims description 13
- 229920000936 Agarose Polymers 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 238000000926 separation method Methods 0.000 description 8
- 239000012148 binding buffer Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 102000028180 Glycophorins Human genes 0.000 description 2
- 108091005250 Glycophorins Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/828—Protein A
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/623,797 US4704366A (en) | 1984-06-22 | 1984-06-22 | Process for binding IgG to protein A |
| US623797 | 1984-06-22 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3109760A Division JPH04234899A (ja) | 1984-06-22 | 1991-04-15 | 免疫グロブリンｇ分子の単離方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6112631A JPS6112631A (ja) | 1986-01-21 |
| JPH0455440B2 true JPH0455440B2 (enExample) | 1992-09-03 |
Family
ID=24499435
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60135808A Granted JPS6112631A (ja) | 1984-06-22 | 1985-06-21 | 免疫グロブリンｇ分子のプロテインａへの結合方法 |
| JP3109760A Granted JPH04234899A (ja) | 1984-06-22 | 1991-04-15 | 免疫グロブリンｇ分子の単離方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3109760A Granted JPH04234899A (ja) | 1984-06-22 | 1991-04-15 | 免疫グロブリンｇ分子の単離方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US4704366A (enExample) |
| JP (2) | JPS6112631A (enExample) |
| DE (1) | DE3521679A1 (enExample) |
| GB (1) | GB2160530B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283323A (en) * | 1985-08-07 | 1994-02-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing immune response |
| US4977247A (en) * | 1986-02-14 | 1990-12-11 | Genex Corporation | Immobilized protein G variants and the use thereof |
| SE459662B (sv) * | 1986-03-21 | 1989-07-24 | Pharmacia Ab | Hybrid-dna-molekyl som kodar foer ett protein med samma igg specificitet som protein g, plasmid innehaallande densamma samt foerfarande foer framstaellning av proteinet |
| US5089605A (en) * | 1987-03-13 | 1992-02-18 | Repligen Corporation | Immobilized immunoglobulin-binding proteins |
| JPS6419024A (en) * | 1987-07-15 | 1989-01-23 | Tosoh Corp | Separation of immunoglobulin g subclass |
| US4981961A (en) * | 1988-09-12 | 1991-01-01 | Bioprobe International, Inc. | Synthetic affinity ligand compositions and methods for purification and recovery of organic molecules |
| US4933435A (en) * | 1989-04-05 | 1990-06-12 | Bioprobe International | Antibody purification process |
| US5151504A (en) * | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
| US5077391A (en) * | 1989-12-01 | 1991-12-31 | Raison Robert L | Purification of immunoglobulin M |
| JPH03185000A (ja) * | 1989-12-15 | 1991-08-12 | Tosoh Corp | プロテインＡと免疫グロブリンＧ（ＩｇＧ）との結合方法 |
| US5200471A (en) * | 1990-11-05 | 1993-04-06 | Minnesota Mining And Manufacturing Company | Biomolecules covalently immobilized with a high bound specific biological activity and method of preparing same |
| US5245016A (en) * | 1991-01-31 | 1993-09-14 | University Of Utah Research Foundation | Pseudomonas maltophilia immunoglobulin binding protein and methods for its use |
| DE69428891T2 (de) * | 1993-03-29 | 2002-06-27 | Minnesota Mining And Mfg. Co., Saint Paul | VERFAHREN ZUR VERBINDUNG VON LIGANDEN IN EINEM PORÖSEN TRÄGER (e.g.AZLAKTON) UND DESSEN ANWENDUNGEN |
| US5593822A (en) * | 1993-12-07 | 1997-01-14 | John Wayne Cancer Institute | IgG depleted serum preparations and methods for antibody production |
| US5561045A (en) * | 1994-01-04 | 1996-10-01 | Intracel Corporation | Detection reagent, article, and immunoassay method |
| AU7241294A (en) * | 1994-04-01 | 1995-10-23 | Unisyn Technologies, Inc. | High salt binding buffer for immunoglobulin purification with a synthetic affinity ligand |
| US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| RU2346701C2 (ru) * | 2002-11-26 | 2009-02-20 | ПиДиЭл БАЙОФАРМА ИНК. | ХИМЕРНЫЕ И ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ ИНТЕГРИНА α5β1, КОТОРЫЕ МОДУЛИРУЮТ АНГИОГЕНЕЗ |
| US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| KR20070009637A (ko) * | 2004-03-24 | 2007-01-18 | 피디엘 바이오파르마 인코포레이티드 | 암 세포 증식을 억제하는 항α5β1 항체의 용도 |
| EP2193148A2 (en) * | 2007-07-27 | 2010-06-09 | Facet Biotech Corporation | Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e) |
| US20100158893A1 (en) * | 2008-12-19 | 2010-06-24 | Baxter International Inc. | Systems and methods for obtaining immunoglobulin from blood |
| WO2011064910A1 (ja) * | 2009-11-25 | 2011-06-03 | パナソニック株式会社 | 免疫測定方法 |
| MX2012007103A (es) | 2009-12-18 | 2012-07-17 | Novartis Ag | Solucion y metodo de lavado por cromatografia de afinidad. |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| SI2783216T1 (sl) | 2011-11-21 | 2019-01-31 | Abaxis, Inc. | Imunološki preskusi ojačanja signala |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| TW201348247A (zh) * | 2012-05-21 | 2013-12-01 | Abbvie Inc | 利用蛋白質ａ親和性層析之非人類抗體之新穎純化 |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| US9206390B2 (en) | 2012-09-02 | 2015-12-08 | Abbvie, Inc. | Methods to control protein heterogeneity |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| TWI691716B (zh) | 2014-08-13 | 2020-04-21 | 美商艾巴希斯公司 | 電漿特異性結合搭配物檢定中之信號放大 |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| PL3331818T3 (pl) | 2015-08-04 | 2024-10-21 | Zoetis Services Llc | Wzmocnienie sygnału w testach plazmonowych partnerów swoistego wiązania na bazie roztworu |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| JP7106187B2 (ja) | 2016-05-11 | 2022-07-26 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを保存する方法 |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US11753438B2 (en) | 2016-05-11 | 2023-09-12 | Cytiva Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| CN109071613A (zh) | 2016-05-11 | 2018-12-21 | 通用电气医疗集团生物工艺研发股份公司 | 分离基质 |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| KR102654470B1 (ko) | 2017-01-30 | 2024-04-05 | 조에티스 서비시즈 엘엘씨 | 용액-기반 플라스몬 특이적-결합 파트너 검정 및 금속성 나노구조체 |
| CN119881293A (zh) | 2018-03-21 | 2025-04-25 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE413986B (sv) * | 1973-03-23 | 1980-07-07 | Exploaterings Ab Tbf | Sett att separera amfipatiska emnen innehallande bade hydrofila och hydrofoba grupper samt gelprodukt for genomforande av separationen |
| US4430318A (en) * | 1978-11-29 | 1984-02-07 | The United States Of America As Represented By The Department Of Health And Human Services | Immunoassay utilizing 125 I Protein A |
| US4230685A (en) * | 1979-02-28 | 1980-10-28 | Northwestern University | Method of magnetic separation of cells and the like, and microspheres for use therein |
| AU570911B2 (en) * | 1981-11-06 | 1988-03-31 | Baylor College Of Medicine | Immunoadsorbent based on immobilized protein a and its use |
-
1984
- 1984-06-22 US US06/623,797 patent/US4704366A/en not_active Expired - Fee Related
-
1985
- 1985-06-17 GB GB08515261A patent/GB2160530B/en not_active Expired
- 1985-06-18 DE DE19853521679 patent/DE3521679A1/de active Granted
- 1985-06-21 JP JP60135808A patent/JPS6112631A/ja active Granted
-
1991
- 1991-04-15 JP JP3109760A patent/JPH04234899A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6112631A (ja) | 1986-01-21 |
| US4704366A (en) | 1987-11-03 |
| DE3521679A1 (de) | 1986-01-02 |
| GB8515261D0 (en) | 1985-07-17 |
| DE3521679C2 (enExample) | 1989-08-24 |
| JPH04234899A (ja) | 1992-08-24 |
| GB2160530A (en) | 1985-12-24 |
| GB2160530B (en) | 1987-10-28 |
| JPH0543719B2 (enExample) | 1993-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0455440B2 (enExample) | ||
| Ey et al. | Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose | |
| CA2611816C (en) | Methods of purifying fc region containing proteins | |
| HU217850B (hu) | Eljárás antitest tisztítására | |
| JPWO1987001597A1 (ja) | β↓２−ミクログロブリン除去カラム | |
| Palombo et al. | Affinity purification of mouse monoclonal IgE using a protein A mimetic ligand (TG19318) immobilized on solid supports | |
| Vassella et al. | Natural anti‐IgE auto‐antibodies interfere with diagnostic IgE determination | |
| JPH06107700A (ja) | Ｆ ＶＩＩＩ／ｖＷＦ複合体吸着のための免疫吸着材 | |
| JPH054075B2 (enExample) | ||
| Jean-Claude et al. | The isolation and characterization of immunoglobulins, antibodies, and their constituent polypeptide chains | |
| Bridonneau et al. | Behaviour of human immunoglobulin G subclasses on thiophilic gels: comparison with hydrophobic interaction chromatography | |
| Finger et al. | Investigations on the specificity of thiophilic interaction for monoclonal antibodies of different subclasses | |
| Ohlson et al. | High-performance liquid affinity chromatographic separation of mouse monoclonal antibodies with protein A silica | |
| Catty et al. | The application of cellulose carbonate to the preparation of water-insoluble immunoadsorbents used in the purification of antibodies to immunoglobulins | |
| JP2024161359A (ja) | 精製方法 | |
| Josić et al. | High-performance liquid affinity chromatography of liver plasma membrane proteins | |
| Ricardo Jr et al. | Effect of pH on the binding between guinea pig IgG isotypes and protein A: evidence for intra-isotypic binding heterogeneity. | |
| Morgan et al. | Electrophoretic desorption of immunoglobulins from immobilised protein A and other ligands | |
| CA1233747A (en) | Process for binding igg to protein a | |
| US4841024A (en) | Purification of antibodies | |
| Poiesi et al. | Protein a, hydroxyapatite and diethylaminoethyl: Evaluation of three procedures for the preparative purification of monoclonal antibodies by high-perfomance liquid chromatography | |
| US8298783B2 (en) | Detecting molecules | |
| JPH0696598B2 (ja) | 抗体の精製法 | |
| JPH0616698A (ja) | ポリクローナル抗体の分離精製方法 | |
| JPH07146280A (ja) | アフィニティクロマトグラフィー用吸着体及びこれを 用いた抗体の分離方法、抗体濃度の測定方法、抗体断 片の精製濃縮方法 |